MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ejca.2025.116065

Медицинская библиотека · European journal of cancer (Oxford, England : 1990) · 2025

Clinical relevance of next-generation sequencing in patients aged 60 years or younger with pancreatic cancer: A Nationwide prospective cohort study.

Strijk Gaby J, van Dongen Jelle C, de Koning Willem, Brosens Lodewijk A A, Cirkel Geert A, Doukas Michail, Sarasqueta Arantza Farina, Groenendijk Floris H, Koerkamp Bas Groot, Th de Hingh Ignace H J, Homs Marjolein Y V, Martens-de Kemp Sanne R, de Vos-Geelen Judith, Wagner Anja, Kooreman Nigel G, Stubbs Andrew P, Wilmink Johanna W, Eijck Casper H J van, Dutch Pancreatic Cancer Group

СтатьяМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND AND AIMS: Pancreatic ductal adenocarcinoma (PDAC) has limited therapeutic options and frequent resistance to standard treatments. This study evaluates the feasibility and clinical impact of comprehensive tumor molecular profiling in PDAC patients aged ≤ 60 years.

METHODS

Nationwide prospective cohort study across 13 Dutch hospitals from April 2021 to June 2024. PDAC patients aged ≤ 60 at any disease stage were included regardless of treatment status. DNA and RNA from tumor samples were isolated from representative, formalin-fixed paraffin-embedded (FFPE) slides for whole-exome sequencing (WES) and whole-transcriptome sequencing (WTS). A multidisciplinary molecular tumor board reviewed results monthly.

RESULTS

Among 318 patients, 88.7 % (282/318) had tumor samples suitable for sequencing. WES and WTS were completed in 175 patients (55.0 %), with WTS alone in 88 (27.7 %). Complete molecular analysis was more often successful in resection specimens than in biopsy samples (79 % vs 33 %; P < .001). Unknown germline mutations in cancer predisposition genes were identified in 4 % (13/318) of patients. Actionable alterations were detected in 13.2 % (42/318), rising to 22.3 % (39/175) among patients with WES and WTS. Actionable targets were found in 92.3 % (12/13) KRAS-wildtype tumors. Only 11 of 42 (26.2 %) patients received tailored therapies.

CONCLUSIONS

Complete molecular profiling in PDAC patients ≤ 60 years showed moderate success (55 %) and limited clinical impact, with actionable findings in 13 % and therapy implementation in 3.5 %. Prioritizing KRAS testing and deeper sequencing in KRAS-wildtype tumors, alongside broader access to targeted therapies, may improve outcomes.

Для цитирования: Strijk Gaby J, van Dongen Jelle C, de Koning Willem, Brosens Lodewijk A A, Cirkel Geert A, Doukas Michail, Sarasqueta Arantza Farina, Groenendijk Floris H, Koerkamp Bas Groot, Th de Hingh Ignace H J, Homs Marjolein Y V, Martens-de Kemp Sanne R, de Vos-Geelen Judith, Wagner Anja, Kooreman Nigel G, Stubbs Andrew P, Wilmink Johanna W, Eijck Casper H J van, Dutch Pancreatic Cancer Group. Clinical relevance of next-generation sequencing in patients aged 60 years or younger with pancreatic cancer: A Nationwide prospective cohort study.. European journal of cancer (Oxford, England : 1990). 2025. DOI: 10.1016/j.ejca.2025.116065.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.